Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hurdles to breakthrough in CAR T cell therapy of solid tumors
Faroogh Marofi, Harun Achmad, Dmitry Olegovich Bokov, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
Ting Yan, Zhu Lingfeng, Jin Chen
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 113
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
Grace Guzman, Megan R. Reed, Kevin Bielamowicz, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 5, pp. 479-489
Open Access | Times Cited: 88
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Xiangyu Wu, Tianhang Li, Rui Jiang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 72
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
Christina Claus, Claudia Ferrara, Christian Klein
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 60
CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies
Kewen Qian, Guangyao Li, Shuyi Zhang, et al.
Deleted Journal (2024) Vol. 2, Iss. 2
Open Access | Times Cited: 11
Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy
Fotios Mpekris, Myrofora Panagi, Antonia Charalambous, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 7, pp. 101626-101626
Open Access | Times Cited: 10
The mechanopathology of the tumor microenvironment: detection techniques, molecular mechanisms and therapeutic opportunities
Simón I. Angeli, Constantina Neophytou, Maria Kalli, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access | Times Cited: 1
Nanotechnology-based in situ cancer vaccines: Mechanisms, design, and recent advances
Gaoli Niu, Hong Wang, Yanhong Zhai, et al.
Nano Today (2024) Vol. 56, pp. 102286-102286
Closed Access | Times Cited: 8
Emerging Preclinical Applications of Humanized Mouse Models in the Discovery and Validation of Novel Immunotherapeutics and Their Mechanisms of Action for Improved Cancer Treatment
Isha Karnik, Zhisheng Her, Shu Hui Neo, et al.
Pharmaceutics (2023) Vol. 15, Iss. 6, pp. 1600-1600
Open Access | Times Cited: 15
Immunotherapies targeting tumor vasculature: challenges and opportunities
Hassan Dianat‐Moghadam, Reza Nedaeinia, Mohsen Keshavarz, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Machine learning analysis reveals tumor stiffness and hypoperfusion as biomarkers predictive of cancer treatment efficacy
Demetris Englezos, Chrysovalantis Voutouri, Triantafyllos Stylianopoulos
Translational Oncology (2024) Vol. 44, pp. 101944-101944
Open Access | Times Cited: 5
Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities
C. Arenas Linares, Anjana Varghese, Aruni Ghose, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13215-13215
Open Access | Times Cited: 13
CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
Dennis Christoph Harrer, Jan Dörrie, Niels Schaft
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2342-2342
Open Access | Times Cited: 9
Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies
Antonio Maria Alviano, Marta Biondi, Erica Grassenis, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment
Xing He, Huanrong Lan, Ketao Jin, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Emerging Hallmarks of the Tumour Microenvironment of Gliomas and the Interplay with Immunotherapy
C. Arenas Linares, Anjana Varghese, Aruni Ghose, et al.
(2023)
Open Access | Times Cited: 6
From barriers to novel strategies: smarter CAR T therapy hits hard to tumors
Muhammad Babar Khawar, Fei Ge, Ali Afzal, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Broadening anticancer spectrum by preprocessing and treatment of T- lymphocytes expressed FcγRI and monoclonal antibodies for refractory cancers
Lei Tang, Qinyi Sun, Mengyuan Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Bridging the age gap: a review of molecularly informed treatments for glioma in adolescents and young adults
Annette Weiser, Astrid Sanchez Bergman, Charbel Machaalani, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
The progress of optional targets and approaches to enhance efficacy of CAR-T for pancreatic ductal adenocarcinoma
Haoyun Xie
(2024), pp. 53-53
Closed Access | Times Cited: 1
Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment
Saade Abdalkareem Jasim, I.M. Farber, Sara Abdalrazzaq M. Noraldeen, et al.
Microvascular Research (2024) Vol. 154, pp. 104691-104691
Closed Access | Times Cited: 1
Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs
Lakshmi Balagopalan, Taylor Moreno, Haiying Qin, et al.
Science Signaling (2024) Vol. 17, Iss. 846
Open Access | Times Cited: 1
Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy
C Carcopino, Ergun Erdoğan, M Henrich, et al.
Immuno-Oncology Technology (2024) Vol. 24, pp. 100739-100739
Open Access | Times Cited: 1
Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy
Zhujiang Dai, Jihong Fu, Xiang Peng, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4796-4796
Open Access | Times Cited: 4
Toward the clinical development of synthetic immunity to cancer
Julie Garcia, Cassandra E. Burnett, Kole T. Roybal
Immunological Reviews (2023) Vol. 320, Iss. 1, pp. 83-99
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top